| Jerry Huo, MD | |
|
38-08 Union Street, Suite 3d, Ny Otolaryngology Pllc, Flushing, NY 11354 | |
| (718) 670-0006 | |
| (718) 701-5883 |
| Full Name | Jerry Huo |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 33 Years |
| Location | 38-08 Union Street, Suite 3d, Flushing, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194766824 | NPI | - | NPPES |
| 01769277 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | NY192242 (New York) | Secondary |
| 207Y00000X | Otolaryngology | 192242 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian/queens | Flushing, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York Queens Medicine And Surgery, P.c. | 4082883673 | 371 |
| Ny Otolaryngology Pllc | 9436254844 | 2 |
News Archive
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.
› Verified 6 days ago
| Entity Name | Ny Otolaryngology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356472492 PECOS PAC ID: 9436254844 Enrollment ID: O20070413000142 |
News Archive
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.
› Verified 6 days ago
| Entity Name | New York Queens Medicine And Surgery, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003114851 PECOS PAC ID: 4082883673 Enrollment ID: O20110817000163 |
News Archive
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jerry Huo, MD 38-08 Union Street, Suite 3d, Ny Otolaryngology Pllc, Flushing, NY 11354 Ph: (718) 670-0006 | Jerry Huo, MD 38-08 Union Street, Suite 3d, Ny Otolaryngology Pllc, Flushing, NY 11354 Ph: (718) 670-0006 |
News Archive
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.
› Verified 6 days ago
Soha Ghossaini, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3526 Francis Lewis Blvd, Flushing, NY 11358 Phone: 718-631-8899 Fax: 718-631-4401 | |
Dr. Jason Brian Wasserman, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3526 Francis Lewis Blvd, Flushing, NY 11358 Phone: 718-631-8899 Fax: 718-631-4401 | |
Dr. Andrew L Blank, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3526 Francis Lewis Blvd, Flushing, NY 11358 Phone: 718-631-8899 Fax: 718-631-4401 | |
Dr. Albert Jen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3808 Union St Ste 3d, Flushing, NY 11354 Phone: 718-670-0006 Fax: 718-701-5883 | |
Pi-tang Lin, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 133-29 41st Road, Suite 2c, Flushing, NY 11355 Phone: 718-939-7750 Fax: 718-939-7568 | |
Dr. Tamekia Wakefield, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3526 Francis Lewis Blvd, Flushing, NY 11358 Phone: 718-631-8899 Fax: 718-631-4401 |